Medtronic Invests in Pi-Cardia for TAVR Innovation

In a significant move to bolster its structural heart offerings, healthcare technology giant Medtronic plc has entered into a strategic investment and distribution agreement with Pi-Cardia Ltd., an Israeli firm specializing in advanced leaflet modification technologies. This collaboration is poised to enhance treatment options for patients undergoing transcatheter aortic valve replacement (TAVR), particularly those with complex anatomies that pose challenges for current procedures.

The core of this partnership centers on Pi-Cardia's innovative ShortCut™ device, the first FDA-cleared technology designed to modify native aortic valve leaflets. This capability is crucial for preventing coronary artery obstruction during valve-in-valve TAVR procedures, a growing concern as TAVR adoption expands to younger and more complex patient populations. The market for TAVR devices is substantial, projected to reach over $15 billion globally by 2028, driven by an aging demographic and the increasing preference for minimally invasive interventions.

Under the terms of the agreement, Medtronic will inject up to $80 million into Pi-Cardia. This investment not only provides capital for further development but also positions Medtronic as the exclusive global commercial distributor of the ShortCut™ device starting in 2027. Leveraging its extensive worldwide Structural Heart division, Medtronic aims to rapidly scale physician access to this technology across key markets including the United States, Europe, and Japan.

Beyond distribution, the deal includes a compelling acquisition option for Medtronic. Should predefined milestones be met, Medtronic has the right to acquire Pi-Cardia for an initial payment of up to $210 million, with potential for additional performance-based earn-out payments. This structure underscores Medtronic's confidence in the technology's future impact and its potential to become a standard of care in complex TAVR scenarios.

Jorie Soskin, vice president and general manager of Structural Heart at Medtronic, highlighted the strategic importance of this investment. "We are investing in technologies that empower physicians to navigate today's structural heart challenges and prepare for tomorrow's opportunities," Soskin stated. "Our engagement with Pi-Cardia aligns with our commitment to cultivating a portfolio that will define the future of TAVR, especially for patients with intricate cardiac structures. We see leaflet modification as a vital component of advanced structural heart care."

Pi-Cardia, founded by Erez Golan and Eyal Kolka, has been supported by a strong syndicate of investors including Sofinnova Partners, Sprig Equity, and Jacques Séguin. Their backing has been instrumental in advancing the company's mission to establish leaflet modification as a routine element in complex TAVR procedures. Erez Golan, CEO of Pi-Cardia, expressed enthusiasm for the partnership, noting Medtronic's global reach and dedication to innovation as key factors in accelerating the adoption of ShortCut™.

This strategic alliance signifies Medtronic's proactive approach to innovation within the rapidly evolving structural heart landscape. By securing access to a first-in-class leaflet modification technology, Medtronic not only addresses a critical unmet need in valve-in-valve TAVR but also reinforces its leadership position and commitment to advancing transcatheter therapies for improved patient outcomes and sustained long-term growth.